AIM2 and glioblastoma: The most advanced DC vaccine, ICT-107, uses autologous DC pulsed with six peptides, two HLA-A1-restricted and four HLA-A2-restricted, which derive from protein expressed and predicted to be abundant in GBM and glioblastoma cancer cells: gp100, MAGE-1, AIM2, HER2, IL13Ra2 and TRP2.